$PRAX News

BTIG Reiterates Buy on Praxis Precision Medicine, Maintains $810 Price Target

Praxis Precision Medicines: Priced For Half Of What I Think It's Worth

Praxis Precision Medicines (PRAX) Enters Into Licensing and Research Collaboration With Remagine Labs

Goldman Sachs Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $447

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

Praxis Precision Medicines And Remagine Labs Announce Research Collaboration And License Agreement To Develop Iontophoretic Transdermal Patch For Delivery Of Ulixacaltamide For Essential Tremor

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Praxis Precision Medicines Announces FDA Extends PDUFA Date To December 27, 2026 For Relutrigine Following Major Amendment Submission; No New Clinical Or Safety Concerns Cited

Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575

Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results

Praxis Precision Medicines Gains After FDA Grants Breakthrough Therapy Designation

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

Praxis Precision Medicines Receives Breakthrough Therapy Designation From FDA For Elsunersen To Treat Seizures Associated With SCN2A Development And Epileptic Encephalopathy

RBC Capital Initiates Coverage On Praxis Precision Medicine with Outperform Rating, Announces Price Target of $449

Praxis Precision Medicines (PRAX) Stock After Mixed POWER1 Trial Results How Does The Valuation Stack Up

Praxis Precision Medicines, Inc. (PRAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study Findings

Praxis' Premium Price May Reflect Unrealistic Market Prospects In Essential Tremor

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference